Cargando…
Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion
PURPOSE: 2021 marks the tenth anniversary of the AMNOG process and brought with it a new German administration—two good reasons to take stock of where we stand today, what has been achieved so far, and how the path of early benefit assessments in Germany should continue. RESULTS: From the perspectiv...
Autores principales: | Bartol, Arne, Dressler, Katrin, Kaskel, Peter, Landsberg, Christiane, Lechner, Cornelia, Petschulies, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525922/ https://www.ncbi.nlm.nih.gov/pubmed/36181565 http://dx.doi.org/10.1007/s00432-022-04379-2 |
Ejemplares similares
-
Zehn Jahre AMNOG-Prozess aus Sicht der Onkologie: Neuland erschlossen, Bebauung geht weiter
por: Bartol, Arne, et al.
Publicado: (2022) -
Implementation of AMNOG: An industry perspective
por: Leverkus, Friedhelm, et al.
Publicado: (2015) -
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023) -
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023) -
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021)